Heron Therapeutics is having a tough day after receiving a Complete Response Letter from the FDA for HTX-011 for management of post-operative pain.
That’s good news for Pacira BioSciences (PCRX +15.3%), and its opioid-free, extended release local anesthetic exparel. RBC late last week said any negative Heron surprise could mean big upside for the highly shorted Pacira.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.